For the first time, a patient suffering from three life-threatening autoimmune diseases has achieved long-term, treatment-free remission thanks to CAR T cell therapy. The case, published in the journal Med, demonstrates how cutting-edge immune cell therapies may offer new hope for patients with complex, therapy-resistant autoimmune conditions.
The patient, a 47-year-old woman, had battled autoimmune hemolytic anemia (AIHA) for over a decade. In AIHA, the immune system mistakenly attacks and destroys red blood cells, leaving patients reliant on frequent blood transfusions to survive. Her condition was further complicated by two additional autoimmune disorders with nearly opposite effects. Immune thrombocytopenia (ITP) caused her immune system to destroy platelets, increasing her risk of dangerous bleeding, while antiphospholipid antibody syndrome (APLAS) elevated her risk of blood clots.
Despite undergoing nine different treatments — including steroids, immune-suppressing medications, and B cell-targeting antibodies — she saw no lasting improvement. By the time she met the team at the University Hospital of Erlangen in Germany, led by immunologist Fabian Müller, she depended on daily blood transfusions and permanent anticoagulation to manage her complex conditions.
A miracle treatment
Because conventional treatments had failed, Müller and his team offered her CD19-directed CAR T therapy, which uses the patient’s own immune cells to target harmful cells. CAR T therapy has been used successfully for certain blood cancers, such as leukemia and lymphoma, but this marks the first time it has been applied to a patient with three distinct autoimmune diseases simultaneously.
To create the therapy, the patient’s T cells were extracted and re-engineered to recognize CD19, a protein found on B cells. This is important as all three of her conditions were mediated by dysregulated B cells producing harmful autoantibodies. Once reinfused, the CAR-T cells hunted down and eliminated these harmful B cells, effectively resetting the patient’s immune system.
The clinical response was rapid. The patient received her final blood transfusion just seven days after the CAR T infusion. Two weeks later, she reported a noticeable improvement in energy and strength, allowing her to perform everyday activities. By day 25, her hemoglobin had returned to normal levels, signaling that her immune system was no longer destroying red blood cells. Simultaneously, her platelet counts stabilized, and her antiphospholipid antibodies, which increase the risk of dangerous clot formation, gradually disappeared and remained negative.
“The treatment was extremely efficient in getting rid of all three autoimmune conditions at once,” Müller said in the press release. “After being sick for more than a decade, the patient is now in treatment-free remission and able to return to an almost normal life. This therapy significantly improved her quality of life.”
Müller explained that CAR T therapy’s effectiveness stems from its ability to eliminate dysregulated B cells throughout the body, targeting both mature and developing populations. When the patient’s B cells returned months later, they were almost entirely naive, indicating a reset of her immune system. Unlike standard B cell-depleting therapies, CAR T therapy appears to provide a deeper, more durable immune correction.
Importantly, the therapy was well-tolerated. The patient did not experience serious side effects such as cytokine release syndrome or neurotoxicity, which can occur with CAR T treatments. Mild elevations in liver enzymes and lower white blood cell counts were noted, but these were likely related to prior treatments rather than the CAR T therapy itself. Nearly a year after her treatment, she remains free of transfusions, anticoagulation, and other medications for her autoimmune conditions.
A single case with broad implications
While this is a single-case report and longer-term studies are required to confirm the safety and efficacy of CAR T therapy in broader autoimmune populations, the implications are profound. Autoimmune diseases are characterized by loss of self-tolerance, where the body’s immune cells attack healthy tissues. Conventional treatments, including steroids and immunosuppressants, often provide only partial or temporary relief, and many patients continue to suffer from life-threatening complications. CAR T therapy provides a mechanism to reset the immune system itself, rather than simply suppressing symptoms.
The significance of this case extends beyond the individual patient. It highlights the potential of precision immunotherapies to treat complex, multi-system autoimmune disorders. For decades, AIHA, ITP, and APLAS were managed separately, with patients often cycling through multiple therapies with limited success. The success of CAR T therapy in this patient demonstrates that it may be possible to address multiple autoimmune conditions simultaneously by targeting the root cause — dysregulated B cells.
While more controlled and expansive clinical trials are essential to understand how CAR T therapy can be safely and effectively used in patients with severe autoimmune diseases, this approach has already been life-changing for this patient. After more than ten years of daily transfusions and constant medical interventions, she can now live without ongoing treatment, experiencing a quality of life she has not known in years.
